ArticleJournal of applied statistics2026
Assessing the performance of longitudinal T-lymphocytes as biomarkers of immune recovery in HIV-infected children with or without TB co-infection.
Article in Journal of applied statistics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In this paper, the receiver operating characteristic (ROC) curve was used to investigate the performance of longitudinal CD4+ T cell counts as a biomarker of disease recovery in HIV-TB co-infected children from sub-Saharan Africa. According to the standard of care for monitoring pediatric HIV infection, routine assessment of immunologic/virologic markers is required. However, due to the lack of well-equipped laboratories and trained personnel, monitoring these markers as regularly as recommended is not feasible in sub-Saharan Africa. Thus, in the absence of routine laboratory monitoring, methods enabling the prediction of patient outcomes from existing CD4+ T-cell data provide a cost-effective alternative to routine monitoring in the region. Simulation studies were carried out to evaluate the performance of the TB-specific ROC model. We found that post-treatment longitudinal CD4+ T cell count had a 79% (95% CI: 0.72-0.86) probability of correctly distinguishing a recovered from non-recovered TB patient compared to a probability of 70% (95% CI: 0.59-0.82) in TB negative patients. Our findings demonstrate that longitudinal CD4+ T-cell counts are reliable indicators of pediatric immune recovery and provide a cost-effective alternative for predicting patient outcomes in the absence of routine laboratory monitoring, particularly HIV RNA determination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.